Innovative mechanisms of action for pharmaceutical cognitive enhancement: A systematic review

Psychiatry Research

Volumn 229, Issue 1-2, 2015, Pages 12-20

  Fond, Guillaume ^a   Micoulaud Franchi, Jean Arthur ^c   Brunel, Lore ^a   Macgregor, Alexandra ^b   Miot, Stéphanie ^e   Lopez, Régis ^b   Richieri, Raphaëlle ^c,d   Abbar, Mocrane ^f   Lancon, Christophe ^c   Repantis, Dimitris ^g  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b MONTPELLIER UNIVERSITY HOSPITAL   (France)

^c HÔPITAL SAINTE MARGUERITE   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

^e INSERM   (France)

^f Laboratoire de Psychopathologie Clinique et Psychanalyse   (France)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Attention; Cognitive enhancement; Healthy adult; Memory; Performance

Indexed keywords

6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; ACETYLSALICYLIC ACID; AMPA RECEPTOR AGONIST; BIPERIDEN; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; CLONIDINE; DOPAMINE UPTAKE INHIBITOR; FARAMPATOR; FEXOFENADINE; GLUCOCORTICOID; GUANFACINE; HYDROCORTISONE; LEVODOPA; MELATONIN; NONSTEROID ANTIINFLAMMATORY AGENT; NOOTROPIC AGENT; PLACEBO; PRAMIPEXOLE; PSYCHOSTIMULANT AGENT; TOLCAPONE; TRIHEXYPHENIDYL; BENZHYDRYL DERIVATIVE; CENTRAL STIMULANT AGENT; METHYLPHENIDATE; MODAFINIL; NICOTINE;

ALERTNESS; ATTENTION; ATTENTION DEFICIT DISORDER; AUTOBIOGRAPHICAL MEMORY; COGNITION; DYSTONIA; EPISODIC MEMORY; EXECUTIVE FUNCTION; HUMAN; HYPERTENSION; LEARNING; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SHORT TERM MEMORY; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; VERBAL MEMORY; WAKEFULNESS; WORKING MEMORY; ADULT; DRUG EFFECTS; MALE;

ADULT; ATTENTION; BENZHYDRYL COMPOUNDS; CENTRAL NERVOUS SYSTEM STIMULANTS; COGNITION; HUMANS; LEVODOPA; MALE; MEMORY, EPISODIC; METHYLPHENIDATE; NICOTINE; NOOTROPIC AGENTS;

EID: 84939444316     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2015.07.006     Document Type: Review

References (103)

1. Andreou C., Moritz S., Veith K., Veckenstedt R., Naber D. Dopaminergic modulation of probabilistic reasoning and overconfidence in errors: a double-blind study. Schizophr. Bull. 2013, 40(3):558-565.
2. Apud J.A., Mattay V., Chen J., Kolachana B.S., Callicott J.H., Rasetti R., Alce G., Iudicello J.E., Akbar N., Egan M.F., Goldberg T.E., Weinberger D.R. Tolcapone improves cognition and cortical information processing in normal human subjects. Neuropsychopharmacology 2007, 32:1011-1020.
3. Artola A., Singer W. Long-term potentiation and NMDA receptors in rat visual cortex. Nature 1987, 330:649-652.
4. Barad M., Bourtchouladze R., Winder D.G., Golan H., Kandel E. Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory. Proc. Natl. Acad. Sci. USA 1998, 95:15020-15025.
5. Bartus R.T., Dean R.L., Beer B., Lippa A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982, 217:408-414.
6. Baudry M., Kramar E., Xu X., Zadran H., Moreno S., Lynch G., Gall C., Bi X. Ampakines promote spine actin polymerization, long-term potentiation, and learning in a mouse model of Angelman syndrome. Neurobiol. Dis. 2012, 47:210-215.
7. Biton B., Bergis O.E., Galli F., Nedelec A., Lochead A.W., Jegham S., Godet D., Lanneau C., Santamaria R., Chesney F., Leonardon J., Granger P., Debono M.W., Bohme G.A., Sgard F., Besnard F., Graham D., Coste A., Oblin A., Curet O., Vige X., Voltz C., Rouquier L., Souilhac J., Santucci V., Gueudet C., Francon D., Steinberg R., Griebel G., Oury-Donat F., George P., Avenet P., Scatton B. SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (1) binding and functional profile. Neuropsychopharmacology 2007, 32:1-16.
8. Block F., Schmidt W., Nolden-Koch M., Schwarz M. Rolipram reduces excitotoxic neuronal damage. Neuroreport 2001, 12:1507-1511.
9. Bower E.A., Moore J.L., Moss M., Selby K.A., Austin M., Meeves S. The effects of single-dose fexofenadine, diphenhydramine, and placebo on cognitive performance in flight personnel. Aviat. Sp. Environ. Med. 2003, 74:145-152.
10. Eickenhorst P., Vitzthum K., Klapp B.F., Groneberg D., Mache S. Neuroenhancement among German university students: motives, expectations, and relationship with psychoactive lifestyle drugs. J. Psychoact. Drugs 2012, 44:418-427.
11. Everitt B.J., Robbins T.W. Central cholinergic systems and cognition. Ann. Rev. Psychol. 1997, 48:649-684.
12. Farah M.J., Illes J., Cook-Deegan R., Gardner H., Kandel E., King P., Parens E., Sahakian B., Wolpe P.R. Neurocognitive enhancement: what can we do and what should we do?. Nat. Rev. Neurosci. 2004, 5:421-425.
13. Farrell S.M., Tunbridge E.M., Braeutigam S., Harrison P.J. COMT Val(158)Met genotype determines the direction of cognitive effects produced by catechol-O-methyltransferase inhibition. Biol. Psychiatry 2012, 71:538-544.
14. FDA, 2013. http://www.fda.org.
15. Floel A., Vomhof P., Lorenzen A., Roesser N., Breitenstein C., Knecht S. Levodopa improves skilled hand functions in the elderly. Eur. J. Neurosci. 2008, 27:1301-1307.
16. Floel A., Garraux G., Xu B., Breitenstein C., Knecht S., Herscovitch P., Cohen L.G. Levodopa increases memory encoding and dopamine release in the striatum in the elderly. Neurobiol. Aging 2008, 29:267-279.
17. Floel A., Breitenstein C., Hummel F., Celnik P., Gingert C., Sawaki L., Knecht S., Cohen L.G. Dopaminergic influences on formation of a motor memory. Ann. Neurol. 2005, 58:121-130.
18. Forlini C., Hall W., Maxwell B., Outram S.M., Reiner P.B., Repantis D., Schermer M., Racine E. Navigating the enhancement landscape. Ethical issues in research on cognitive enhancers for healthy individuals. Eur. Mol. Biol. Organ. Rep. 2013, 14:123-128.
19. Franke A.G., Bagusat C., Rust S., Engel A., Lieb K. Substances used and prevalence rates of pharmacological cognitive enhancement among healthy subjects. Eur. Arch. Psychiatry Clin. Neurosci. 2014, 264(Suppl. 1):S83-S90.
20. Franke A.G., Christmann M., Bonertz C., Fellgiebel A., Huss M., Lieb K. Use of coffee, caffeinated drinks and caffeine tablets for cognitive enhancement in pupils and students in Germany. Pharmacopsychiatry 2011, 44:331-338.
21. Franke A.G., Bagusat C., Dietz P., Hoffmann I., Simon P., Ulrich R., Lieb K. Use of illicit and prescription drugs for cognitive or mood enhancement among surgeons. BMC Med. 2013, 11:102.
22. de Frias C.M., Annerbrink K., Westberg L., Eriksson E., Adolfsson R., Nilsson L.G. Catechol O-methyltransferase Val158Met polymorphism is associated with cognitive performance in nondemented adults. J. Cogn. Neurosci. 2005, 17:1018-1025.
23. Froestl W., Muhs A., Pfeifer A. Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors. J. Alzheimers Dis. 2012, 32:793-887.
24. Glannon W. Psychopharmacology and memory. J. Med. Ethics 2006, 32:74-78.
25. Gorfine T., Yeshurun Y., Zisapel N. Nap and melatonin-induced changes in hippocampal activation and their role in verbal memory consolidation. J. Pineal Res. 2007, 43:336-342.
26. Graef S., Schonknecht P., Sabri O., Hegerl U. Cholinergic receptor subtypes and their role in cognition, emotion, and vigilance control: an overview of preclinical and clinical findings. Psychopharmacology 2011, 215:205-229.
27. Grossman L., Stewart A., Gaikwad S., Utterback E., Wu N., Dileo J., Frank K., Hart P., Howard H., Kalueff A.V. Effects of piracetam on behavior and memory in adult zebrafish. Brain Res. Bull. 2011, 85:58-63.
28. Gualtieri F., Manetti D., Romanelli M.N., Ghelardini C. Design and study of piracetam-like nootropics, controversial members of the problematic class of cognition-enhancing drugs. Curr. Pharm. Des. 2002, 8:125-138.
29. Guthrie S.K., Manzey L., Scott D., Giordani B., Tandon R. Comparison of central and peripheral pharmacologic effects of biperiden and trihexyphenidyl in human volunteers. J. Clin. Psychopharmacol. 2000, 20:77-83.
30. Han D.H., Yoon S.J., Sung Y.H., Lee Y.S., Kee B.S., Lyoo I.K., Renshaw P.F., Cho S.C. A preliminary study: novelty seeking, frontal executive function, and dopamine receptor (D2) TaqI A gene polymorphism in patients with methamphetamine dependence. Compr. Psychiatry 2008, 49:387-392.
31. Harris J. Moral enhancement and freedom. Bioethics 2011, 25:102-111.
32. Heinz A., Kipke R., Heimann H., Wiesing U. Cognitive neuroenhancement: false assumptions in the ethical debate. J. Med. Ethics 2012, 38:372-375.
33. Heishman S.J., Kleykamp B.A., Singleton E.G. Meta-analysis of the acute effects of nicotine and smoking on human performance. Psychopharmacology 2010, 210:453-469.
34. Henckens M.J., van Wingen G.A., Joels M., Fernandez G. Time-dependent effects of cortisol on selective attention and emotional interference: a functional MRI study. Front. Integr. Neurosci. 2012, 6:66.
35. Het S., Ramlow G., Wolf O.T. A meta-analytic review of the effects of acute cortisol administration on human memory. Psychoneuroendocrinology 2005, 30:771-784.
36. Hong W., Werling L.L. Evidence that the sigma(1) receptor is not directly coupled to G proteins. Eur. J. Pharmacol. 2000, 408:117-125.
37. Ingvar M., Ambros-Ingerson J., Davis M., Granger R., Kessler M., Rogers G.A., Schehr R.S., Lynch G. Enhancement by an ampakine of memory encoding in humans. Exp. Neurol. 1997, 146:553-559.
38. Jakala P., Sirvio J., Riekkinen M., Koivisto E., Kejonen K., Vanhanen M., Riekkinen P. Guanfacine and clonidine, alpha 2-agonists, improve paired associates learning, but not delayed matching to sample, in humans. Neuropsychopharmacology 1999, 20:119-130.
39. de Jongh R., Bolt I., Schermer M., Olivier B. Botox for the brain: enhancement of cognition, mood and pro-social behavior and blunting of unwanted memories. Neurosci. Biobehav. Rev. 2008, 32:760-776.
40. Kintscher U. Reuptake inhibitors of dopamine, noradrenaline, and serotonin. Handb. Exp. Pharmacol. 2012, 209:339-347.
41. Knecht S., Breitenstein C., Bushuven S., Wailke S., Kamping S., Floel A., Zwitserlood P., Ringelstein E.B. Levodopa: faster and better word learning in normal humans. Ann. Neurol. 2004, 56:20-26.
42. Koh M.T., Rosenzweig-Lipson S., Gallagher M. Selective GABA(A) alpha5 positive allosteric modulators improve cognitive function in aged rats with memory impairment. Neuropharmacology 2013, 64:145-152.
43. Larson J., Jessen R.E., Uz T., Arslan A.D., Kurtuncu M., Imbesi M., Manev H. Impaired hippocampal long-term potentiation in melatonin MT2 receptor-deficient mice. Neurosci. Lett. 2006, 393:23-26.
44. Lelkes Z., Alfoldi P., Erdos A., Benedek G. Rolipram, an antidepressant that increases the availability of cAMP, transiently enhances wakefulness in rats. Pharmacol. Biochem. Behav. 1998, 60:835-839.
45. Levin E.D., McClernon F.J., Rezvani A.H. Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology 2006, 184:523-539.
46. Lynch G., Kessler M., Rogers G., Ambros-Ingerson J., Granger R., Schehr R.S. Psychological effects of a drug that facilitates brain AMPA receptors. Int. Clin. Psychopharmacol. 1996, 11:13-19.
47. Lynch G., Granger R., Ambros-Ingerson J., Davis C.M., Kessler M., Schehr R. Evidence that a positive modulator of AMPA-type glutamate receptors improves delayed recall in aged humans. Exp. Neurol. 1997, 145:89-92.
48. Magalona S.C., Rasetti R., Chen J., Chen Q., Gold I., Decot H., Callicott J.H., Berman K.F., Apud J.A., Weinberger D.R., Mattay V.S. Effect of tolcapone on brain activity during a variable attentional control task: a double-blind, placebo-controlled, counter-balanced trial in healthy volunteers. CNS Drugs 2013, 27:663-673.
49. Maier L.J., Liechti M.E., Herzig F., Schaub M.P. To dope or not to dope: neuroenhancement with prescription drugs and drugs of abuse among Swiss university students. PLoS One 2013, 8:e77967.
50. Mansfield L., Mendoza C., Flores J., Meeves S.G. Effects of fexofenadine, diphenhydramine, and placebo on performance of the test of variables of attention (TOVA). Ann. Allergy Asthma Immunol. 2003, 90:554-559.
51. Matsuno K., Senda T., Kobayashi T., Mita S. Involvement of sigma 1 receptor in (+)-N-allylnormetazocine-stimulated hippocampal cholinergic functions in rats. Brain Res. 1995, 690:200-206.
52. Mattay V.S., Callicott J.H., Bertolino A., Heaton I., Frank J.A., Coppola R., Berman K.F., Goldberg T.E., Weinberger D.R. Effects of dextroamphetamine on cognitive performance and cortical activation. Neuroimage 2000, 12:268-275.
53. Mattay V.S., Goldberg T.E., Fera F., Hariri A.R., Tessitore A., Egan M.F., Kolachana B., Callicott J.H., Weinberger D.R. Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc. Natl. Acad. Sci. USA 2003, 100:6186-6191.
54. Maurice T., Phan V.L., Urani A., Kamei H., Noda Y., Nabeshima T. Neuroactive neurosteroids as endogenous effectors for the sigma1 (sigma1) receptor: pharmacological evidence and therapeutic opportunities. Jpn. J. Pharmacol. 1999, 81:125-155.
55. McCabe S.E., West B.T., Teter C.J., Boyd C.J. Trends in medical use, diversion, and nonmedical use of prescription medications among college students from 2003 to 2013: connecting the dots. Addict. Behav. 2014, 39:1176-1182.
56. McGeer P.L., Schulzer M., McGeer E.G. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 1996, 47:425-432.
57. McGeer P.L., McGeer E., Rogers J., Sibley J. Anti-inflammatory drugs and Alzheimer disease. Lancet 1990, 335:1037.
58. Micallef J., Rey M., Eusebio A., Audebert C., Rouby F., Jouve E., Tardieu S., Blin O. Antiparkinsonian drug-induced sleepiness: a double-blind placebo-controlled study of l-dopa, bromocriptine and pramipexole in healthy subjects. Br. J. Clin. Pharmacol. 2009, 67:333-340.
59. Micoulaud-Franchi J.A., Vion-Dury J., Lancon C. Neuroenhancement in healthy subject? A French case study. Therapie 2012, 67:213-221.
60. Micoulaud-Franchi J.A., MacGregor A., Fond G. A preliminary study on cognitive enhancer consumption behaviors and motives of French Medicine and Pharmacology students. Eur. Rev. Med. Pharmacol. Sci. 2014, 18:1875-1878.
61. Milic M., Timic T., Joksimovic S., Biawat P., Rallapalli S., Divljakovic J., Radulovic T., Cook J.M., Savic M.M. PWZ-029, an inverse agonist selective for alpha(5) GABAA receptors, improves object recognition, but not water-maze memory in normal and scopolamine-treated rats. Behav. Brain Res. 2013, 241:206-213.
62. Molas S., Dierssen M. The role of nicotinic receptors in shaping and functioning of the glutamatergic system: a window into cognitive pathology. Neurosci. Biobehav. Rev. 2014, 2:315-325.
63. Mondadori C, Classen W, Borkowski J, Ducret T, Buerki H, Schadé A Effects of oxiracetam on learning and memory in animals: comparison with piracetam. Clin. Neuropharmacol. 1986, 9(Suppl. 3):S27-S38.
64. Muller U., Clark L., Lam M.L., Moore R.M., Murphy C.L., Richmond N.K., Sandhu R.S., Wilkins I.A., Menon D.K., Sahakian B.J., Robbins T.W. Lack of effects of guanfacine on executive and memory functions in healthy male volunteers. Psychopharmacology 2005, 182:205-213.
65. Oranje B., Gispen-de Wied C.C., Westenberg H.G., Kemner C., Verbaten M.N., Kahn R.S. No effects of l-dopa and bromocriptine on psychophysiological parameters of human selective attention. J. Psychopharmacol. 2006, 20:789-798.
66. Otmakhova N.A., Lisman J.E. D1/D5 dopamine receptors inhibit depotentiation at CA1 synapses via cAMP-dependent mechanism. J. Neurosci. 1998, 18:1270-1279.
67. Pizzagalli D.A., Evins A.E., Schetter E.C., Frank M.J., Pajtas P.E., Santesso D.L., Culhane M. Single dose of a dopamine agonist impairs reinforcement learning in humans: behavioral evidence from a laboratory-based measure of reward responsiveness. Psychopharmacology 2008, 196:221-232.
68. Pomara N., Yi L., Belzer K., Facelle T.M., Willoughby L.M., Sidtis J.J. Retrograde facilitation of verbal memory by trihexyphenidyl in healthy elderly with and without the APOE epsilon4 allele. Eur. Neuropsychopharmacol. 2010, 20:467-472.
69. Repantis D. Antidepressants for neuroenhancement in healthy individuals: a systematic review. Poiesis Praxis 2009, 6:139-174.
70. Repantis D., Laisney O., Heuser I. Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: a systematic review. Pharmacol. Res. 2010, 61:473-481.
71. Repantis D., Schlattmann P., Laisney O., Heuser I. Modafinil and methylphenidate for neuroenhancement in healthy individuals: a systematic review. Pharmacol. Res. 2010, 62:187-206.
72. Rimmele U., Spillmann M., Bartschi C., Wolf O.T., Weber C.S., Ehlert U., Wirtz P.H. Melatonin improves memory acquisition under stress independent of stress hormone release. Psychopharmacology 2009, 202:663-672.
73. Roeper J. Dissecting the diversity of midbrain dopamine neurons. Trends Neurosci. 2013, 36:336-342.
74. Roussos P., Giakoumaki S.G., Bitsios P. Tolcapone effects on gating, working memory, and mood interact with the synonymous catechol-O-methyltransferase rs4818c/g polymorphism. Biol. Psychiatry 2009, 66:997-1004.
75. Rutten K., Prickaerts J., Blokland A. Rolipram reverses scopolamine-induced and time-dependent memory deficits in object recognition by different mechanisms of action. Neurobiol. Learn. Mem. 2006, 85:132-138.
76. Rutten K., Prickaerts J., Hendrix M., van der Staay F.J., Sik A., Blokland A. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors. Eur. J. Pharmacol. 2007, 558:107-112.
77. Samartgis J.R., Schachte L., Hazi A., Crowe S.F. Piracetam, an AMPAkine drug, facilitates memory consolidation in the day-old chick. Pharmacol. Biochem. Behav. 2012, 103:353-358.
78. Scheuer K., Rostock A., Bartsch R., Muller W.E. Piracetam improves cognitive performance by restoring neurochemical deficits of the aged rat brain. Pharmacopsychiatry 1999, 32(Suppl. 1):10-16.
79. Schlosser N., Wolf O.T., Fernando S.C., Riedesel K., Otte C., Muhtz C., Beblo T., Driessen M., Lowe B., Wingenfeld K. Effects of acute cortisol administration on autobiographical memory in patients with major depression and healthy controls. Psychoneuroendocrinology 2010, 35:316-320.
80. Schlosser N., Wolf O.T., Fernando S.C., Terfehr K., Otte C., Spitzer C., Beblo T., Driessen M., Lowe B., Wingenfeld K. Effects of acute cortisol administration on response inhibition in patients with major depression and healthy controls. Psychiatry Res. 2013, 209:439-446.
81. Schnider A., Guggisberg A., Nahum L., Gabriel D., Morand S. Dopaminergic modulation of rapid reality adaptation in thinking. Neuroscience 2010, 167:583-587.
82. Schulz K.P., Clerkin S.M., Fan J., Halperin J.M., Newcorn J.H. Guanfacine modulates the influence of emotional cues on prefrontal cortex activation for cognitive control. Psychopharmacology 2013, 226:261-271.
83. Smith M.E., Farah M.J. Are prescription stimulants "smart pills"? The epidemiology and cognitive neuroscience of prescription stimulant use by normal healthy individuals. Psychol. Bull. 2011, 137:717-741.
84. Son J.H., Winzer-Serhan U.H. Expression of neuronal nicotinic acetylcholine receptor subunit mRNAs in rat hippocampal GABAergic interneurons. J. Comput. Neurol. 2008, 511:286-299.
85. Terfehr K., Wolf O.T., Schlosser N., Fernando S.C., Otte C., Muhtz C., Beblo T., Driessen M., Spitzer C., Lowe B., Wingenfeld K. Hydrocortisone impairs working memory in healthy humans, but not in patients with major depressive disorder. Psychopharmacology 2011, 215:71-79.
86. Teter C.J., Falone A.E., Cranford J.A., Boyd C.J., McCabe S.E. Nonmedical use of prescription stimulants and depressed mood among college students: frequency and routes of administration. J. Subst. Abus. Treat. 2010, 38:292-298.
87. Theunissen E.L., Jonkman L.M., Kuypers K.P., Ramaekers J.G. A combined neurophysiological and behavioural study into the stimulating effects of fexofenadine on performance. J. Psychopharmacol. 2006, 20:496-505.
88. Theunissen E.L., Elvira Jde L., van den Bergh D., Ramaekers J.G. Comparing the stimulant effects of the H1-antagonist fexofenadine with 2 psychostimulants, modafinil and methylphenidate. J. Clin. Psychopharmacol. 2009, 29:439-443.
89. Tiplady B., Bowness E., Stien L., Drummond G. Selective effects of clonidine and temazepam on attention and memory. J. Psychopharmacol. 2005, 19:259-265.
90. Trofimov S.S., Voronina T.A., Guzevatykh L.S. Early postnatal effects of noopept and piracetam on declarative and procedural memory of adult male and female rats. Bull. Exp. Biol. Med. 2005, 139:683-687.
91. Tully T., Bourtchouladze R., Scott R., Tallman J. Targeting the CREB pathway for memory enhancers. Nat. Rev. Drug Discov. 2003, 2:267-277.
92. Tushmalova N.A., Pragina L.L., Inozemtsev A.N., Gumargalieva K.Z., Solov'ev A.G., Burlakova E.B. Effect of low doses of piracetam on conditional reflex memory in rats. Biulleten Eksp. Biol. Med. 1995, 120:60-61.
93. Vacchiano C., Moore J., Rice G.M., Crawley G. Fexofenadine effects on cognitive performance in aviators at ground level and simulated altitude. Aviat. Sp. Environ. Med. 2008, 79:754-760.
94. Wade L., Forlini C., Racine E. Generating genius: how an Alzheimer's drug became considered a 'cognitive enhancer' for healthy individuals. BMC Med. Ethics 2014, 15:37.
95. Wang M., Wong A.H., Liu F. Interactions between NMDA and dopamine receptors: a potential therapeutic target. Brain Res. 2012, 1476:154-163.
96. Watson S., Horton K., Bulmer S., Carlile J., Corcoran C., Gallagher P., Ferrier I.N. Effect of aspirin on hypothalamic-pituitary-adrenal function and on neuropsychological performance in healthy adults: a pilot study. Psychopharmacology 2009, 205:151-155.
97. Wezenberg E., Verkes R.J., Sabbe B.G., Ruigt G.S., Hulstijn W. Modulation of memory and visuospatial processes by biperiden and rivastigmine in elderly healthy subjects. Psychopharmacology 2005, 181:582-594.
98. Wezenberg E., Verkes R.J., Ruigt G.S., Hulstijn W., Sabbe B.G. Acute effects of the ampakine farampator on memory and information processing in healthy elderly volunteers. Neuropsychopharmacology 2007, 32:1272-1283.
99. Wilens T.E., Adler L.A., Adams J., Sgambati S., Rotrosen J., Sawtelle R., Utzinger L., Fusillo S. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J. Am. Acad. Child Adolesc. Psychiatry 2008, 47:21-31.
100. Wolf O.T. HPA axis and memory. Best Pract. Res. Clin. Endocrinol. Metab. 2003, 17:287-299.
101. Woolf N.J. Cholinergic systems in mammalian brain and spinal cord. Prog. Neurobiol. 1991, 37:475-524.
102. Yakel J.L. Cholinergic receptors: functional role of nicotinic ACh receptors in brain circuits and disease. Pflug. Arch. 2013, 465(4):441-450.
103. Yesavage J.A., Mumenthaler M.S., Taylor J.L., Friedman L., O'Hara R., Sheikh J., Tinklenberg J., Whitehouse P.J. Donepezil and flight simulator performance: effects on retention of complex skills. Neurology 2002, 59:123-125.